Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study

[1]  C. Castro,et al.  Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer , 2019, International journal of cancer.

[2]  J. Borrás,et al.  Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain , 2019, Breast Cancer Research and Treatment.

[3]  B. Thürlimann,et al.  Impact of subtypes and comorbidities on breast cancer relapse and survival in population-based studies. , 2018, Breast.

[4]  J. Cuzick,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  L. Holmberg,et al.  Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity , 2018, Breast Cancer Research and Treatment.

[6]  Maria Carmen De Santis,et al.  Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy , 2018, Medical Oncology.

[7]  V. Tjan-Heijnen,et al.  Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer , 2018, Current Treatment Options in Oncology.

[8]  M. Thill,et al.  [The 20-year results of 5‑year hormone therapy in breast cancer : Early Breast Cancer Trialists' Collaborative Group (EBCTCG)]. , 2018, Der Internist.

[9]  M. Tadesse,et al.  Initiation of Adjuvant Endocrine Therapy in Black and White Women With Breast Cancer , 2017, Clinical breast cancer.

[10]  R. Mansel,et al.  Quality indicators in breast cancer care: An update from the EUSOMA working group. , 2017, European journal of cancer.

[11]  Jason P Fine,et al.  Practical recommendations for reporting Fine‐Gray model analyses for competing risk data , 2017, Statistics in medicine.

[12]  M. Higgins,et al.  Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer , 2017, Breast Care.

[13]  M. Holiday-Goodman,et al.  Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory , 2017, Breast cancer : basic and clinical research.

[14]  Dawn L Hershman,et al.  Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer. , 2016, JAMA oncology.

[15]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[16]  Bernd Holleczek,et al.  Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. , 2015, European journal of cancer.

[17]  N. Tinari,et al.  Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. , 2015, Clinical breast cancer.

[18]  Vydmantas Atkocius,et al.  Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  H. Cohen,et al.  Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Ardanaz,et al.  Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study. , 2013, Gynecologic oncology.

[21]  A. Thind,et al.  Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication , 2013, Breast Cancer Research and Treatment.

[22]  Sally W. Vernon,et al.  Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review , 2012, Breast Cancer Research and Treatment.

[23]  A. Neugut,et al.  Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL) , 2012, Breast Cancer Research and Treatment.

[24]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Dawn L. Hershman,et al.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.

[26]  Dawn L Hershman,et al.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Federico,et al.  Variation in 'standard care' for breast cancer across Europe: a EUROCARE-3 high resolution study. , 2010, European journal of cancer.

[28]  L. Jackson,et al.  Neoadjuvant endocrine treatment in primary breast cancer - review of literature. , 2009, Breast.

[29]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[30]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Menard.  Applied Logistic Regression Analysis , 1996 .

[32]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[33]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[34]  M. Rezai,et al.  Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Jacques Ferlay,et al.  International rules for multiple primary cancers. , 2005, Asian Pacific journal of cancer prevention : APJCP.

[36]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.